Human Coagulation Factor XI
Human coagulation factor XI is one of the key factors in the coagulation process. The following is an introduction to its basic information, clinical significance, and related testing aspects:
Basic Information
The Rosenthal factor, also known as antihemophilic globulin C, exists in normal plasma in its zymogen form and is non-covalently bound to high molecular weight kininogen. FXI can be activated by FXIIa and thrombin, and it also has the ability to self-activate. Its main function is to activate FIX to FIXa in the presence of calcium ions. FXI, along with FXII, prekallikrein, and high molecular weight kininogen, participates in the contact phase of blood coagulation. Only a portion of FXI is consumed during blood coagulation, so it can be found in serum and plasma. Deficiency of FXI can lead to bleeding disorders.
Clinical significance
FXI deficiency can lead to coagulation disorders, and patients may experience an increased tendency to bleed, such as skin ecchymosis, epistaxis, gingival bleeding, menorrhagia, etc. In severe cases, deep tissue bleeding and joint bleeding may occur, affecting the patient's quality of life and health. Additionally, in some thrombotic diseases, such as myocardial infarction and cerebral infarction, the activity of FXI may change, and there is a certain correlation with the occurrence and development of the disease.
Detection method
The commonly used detection method is the FXI ELISA kit based on ELISA technology, which quantitatively detects the content of FXI in plasma to assist in the clinical diagnosis of related diseases.
For related products, please refer to
Human Coagulation Factor XI (F11) ELISA Kit - Elisa Kits, High Quality Immunoassay Kits - |DLdevelop
Basic Information
The Rosenthal factor, also known as antihemophilic globulin C, exists in normal plasma in its zymogen form and is non-covalently bound to high molecular weight kininogen. FXI can be activated by FXIIa and thrombin, and it also has the ability to self-activate. Its main function is to activate FIX to FIXa in the presence of calcium ions. FXI, along with FXII, prekallikrein, and high molecular weight kininogen, participates in the contact phase of blood coagulation. Only a portion of FXI is consumed during blood coagulation, so it can be found in serum and plasma. Deficiency of FXI can lead to bleeding disorders.
Clinical significance
FXI deficiency can lead to coagulation disorders, and patients may experience an increased tendency to bleed, such as skin ecchymosis, epistaxis, gingival bleeding, menorrhagia, etc. In severe cases, deep tissue bleeding and joint bleeding may occur, affecting the patient's quality of life and health. Additionally, in some thrombotic diseases, such as myocardial infarction and cerebral infarction, the activity of FXI may change, and there is a certain correlation with the occurrence and development of the disease.
Detection method
The commonly used detection method is the FXI ELISA kit based on ELISA technology, which quantitatively detects the content of FXI in plasma to assist in the clinical diagnosis of related diseases.
For related products, please refer to
Human Coagulation Factor XI (F11) ELISA Kit - Elisa Kits, High Quality Immunoassay Kits - |DLdevelop
